VistaGen Therapeutics (VTGN) Revenue & Revenue Breakdown
VistaGen Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.06M
Latest Revenue (Q)
$183.00K
Main Segment (Y)
License
Main Geography (Y)
License
VistaGen Therapeutics Revenue by Period
VistaGen Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-03-31 | $1.06M | -568.10% |
2023-03-31 | $-227.30K | -120.50% |
2022-03-31 | $1.11M | 1.78% |
2021-03-31 | $1.09M | 100.00% |
2020-03-31 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-03-31 | - | -100.00% |
2017-03-31 | $1.25M | 100.00% |
2016-03-31 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-03-31 | - | -100.00% |
2013-03-31 | $200.40K | -85.07% |
2012-03-31 | $1.34M | 100.00% |
2010-12-31 | - | 100.00% |
2009-12-31 | - | 100.00% |
2008-12-31 | - | 100.00% |
2007-12-31 | - | - |
VistaGen Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $183.00K | 117.86% |
2024-06-30 | $84.00K | -57.43% |
2024-03-31 | $197.30K | -52.04% |
2023-12-31 | $411.40K | 48.15% |
2023-09-30 | $277.70K | 56.36% |
2023-06-30 | $177.60K | 1.14% |
2023-03-31 | $175.60K | -2.23% |
2022-12-31 | $179.60K | -120.12% |
2022-09-30 | $-892.50K | -387.81% |
2022-06-30 | $310.10K | 697.17% |
2022-03-31 | $38.90K | -89.13% |
2021-12-31 | $357.90K | -0.03% |
2021-09-30 | $358.00K | 1.10% |
2021-06-30 | $354.10K | -19.87% |
2021-03-31 | $441.90K | 40.91% |
2020-12-31 | $313.60K | -6.11% |
2020-09-30 | $334.00K | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | -100.00% |
2017-03-31 | $1.25B | 99800.00% |
2016-12-31 | $1.25M | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | 100.00% |
2013-06-30 | - | 100.00% |
2013-03-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2012-09-30 | - | -100.00% |
2012-06-30 | $200.40K | -57.26% |
2012-03-31 | $468.93K | 19727.95% |
2011-12-31 | $2.37K | -99.25% |
2011-09-30 | $316.29K | -42.97% |
2011-06-30 | $554.62K | 100.00% |
2011-03-31 | - | 100.00% |
2010-12-31 | - | 100.00% |
2010-09-30 | - | 100.00% |
2010-06-30 | - | 100.00% |
2010-03-31 | - | 100.00% |
2009-12-31 | - | 100.00% |
2009-09-30 | - | 100.00% |
2009-06-30 | - | 100.00% |
2009-03-31 | - | 100.00% |
2008-12-31 | - | 100.00% |
2008-09-30 | - | 100.00% |
2008-06-30 | - | 100.00% |
2008-03-31 | - | - |
VistaGen Therapeutics Revenue Breakdown
VistaGen Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Mar 22 |
---|---|
License | $1.11M |
Latest
Quarterly Revenue by Product
Product/Service | Jun 23 | Mar 22 |
---|---|---|
License | $177.60K | $39.00K |
Latest
VistaGen Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
Country | Mar 22 |
---|---|
License | $1.11M |
Latest
Quarterly Revenue by Country
Country | Mar 22 |
---|---|
License | $39.00K |
Latest
VistaGen Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
ACIU | AC Immune SA | $14.80M | - |
KZR | Kezar Life Sciences | $7.00M | - |
HSTO | Histogen | $3.77M | $5.00K |
SYBX | Synlogic | $3.37M | - |
XBIO | Xenetic Biosciences | $2.54M | $614.24K |
VTGN | VistaGen Therapeutics | $1.06M | $183.00K |
BPTH | Bio-Path | - | - |
COCP | Cocrystal Pharma | - | - |
CYTO | Altamira Therapeutics | - | $52.73K |
REVB | Revelation Biosciences | - | - |
FWBI | Entero Therapeutics | - | - |
ENTX | Entera Bio | - | $42.00K |
TPST | Tempest Therapeutics | - | - |
DRMA | Dermata Therapeutics | - | - |
CFRX | ContraFect | - | - |
EFTR | eFFECTOR Therapeutics | - | - |
QNRX | Quoin Pharmaceuticals | - | - |